

Ha

Kn

Li

SS

SF

SH

Wa

WL

Wi



PAN MERSEY AREA PRESCRIBING COMMITTEE
 PRESCRIBING POLICY STATEMENT
 REF: PS65 FINAL
 FIRST APC BOARD DATE: 28 MAY 2014
 LAST APC BOARD DATE: 28 MAR 2018



Pan Mersey
 Area Prescribing Committee

GOLIMUMAB injection (Simponi®) in rheumatological conditions

RED

The Pan Mersey Area Prescribing Committee recommends the prescribing of golimumab injection (Simponi®) for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and in patients fitting other criteria commissioned by Pan Mersey CCGs, as listed below.

Rheumatoid arthritis (RA): The Pan Mersey Area Prescribing Committee (APC) recommends prescribing golimumab injection for rheumatoid arthritis in accordance with criteria in [NICE TA225](#) (June 2011), in accordance with [NICE TA375](#) (January 2016), and with the [Pan Mersey Rheumatoid Arthritis Biologics Pathway](#). NICE TA375 recommends golimumab with methotrexate, as a treatment option for adults with severe active rheumatoid arthritis (DAS28>5.1) who have had an inadequate response to intensive therapy with a combination of disease-modifying anti-rheumatic drugs (DMARDs) only with the discount agreed in the patient access scheme (PAS). The Pan Mersey RA Biologics Pathway recommends golimumab, in combination with methotrexate, as a treatment option for adults with severe active rheumatoid arthritis who have had an inadequate response to two or more DMARDs or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event. The Pan Mersey RA biologics pathway recommends golimumab as an option in patients fitting NICE criteria who have not responded adequately to rituximab, and recommends use with non-methotrexate DMARDs as an option in patients who cannot have methotrexate.

Psoriatic arthritis (PsA): The Pan Mersey APC recommends prescribing golimumab injection for psoriatic arthritis in accordance with the criteria in [NICE TA220](#) (April 2011), and in accordance with the [Pan Mersey Psoriatic Arthritis Biologics Pathway](#). The Pan Mersey PsA Biologics Pathway recommends golimumab as an option in psoriatic arthritis of defined severity not responding to two or more DMARDs and recommends alternative biologic treatment if initial biologic treatment fails.

Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (NRASpA): The Pan Mersey APC recommends prescribing golimumab injection for AS and NRASpA in accordance with [NICE TA383](#) (February 2016), [NICE TA497](#) (January 2018) and [Pan Mersey AS and Axial SpA pathway](#).

Planned conception in patients with active inflammatory arthritis: The Pan Mersey APC recommends prescribing golimumab injection for male and female patients with rheumatoid arthritis, psoriatic arthritis or active spondyloarthritis as an option in accordance with the [criteria](#) commissioned by Pan Mersey CCGs for patients wishing to conceive.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.